Fostemsavir

Cat. No.: HY-15440A

CAS No.: 864953-29-7

Molecular Formula: $C_{25}H_{26}N_7O_8P$

Molecular Weight: 583.49

Target: HIV

Pathway: Anti-infection

Storage:

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	2 years
	-20°C	1 year



SOLVENT & SOLUBILITY

In Vitro

DMSO : ≥ 100 mg/mL (171.38 mM)

H_2O : 20 mg/mL (34.28 mM; Need ultrasonic)

* "≥" means soluble, but saturation unknown.

Preparing Stock Solutions

Concentration \ Solvent \ Mass	1 mg	5 mg	10 mg
1 mM	1.7138 mL	8.5691 mL	17.1383 mL
5 mM	0.3428 mL	1.7138 mL	3.4277 mL
10 mM	0.1714 mL	0.8569 mL	1.7138 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

1. Add each solvent one by one: PBS
   Solubility: 8.33 mg/mL (14.28 mM); Clear solution; Need ultrasonic and warming and heat to 60°C

BIOLOGICAL ACTIVITY

Description

Fostemsavir (BMS-663068) is the phosphonooxymethyl prodrug of BMS-626529. Fostemsavir (BMS-663068) is a novel attachment inhibitor that targets HIV-1 gp120 and prevents its binding to $CD4^+$ T cells.

IC_{50} & Target

HIV-1

In Vivo

Fostemsavir (BMS-663068) has good antiviral activity in subjects infected with virus shown to be susceptible (IC_{50}, <100 nM) to the agent[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

[1]. Nowicka-Sans B, et al. In vitro antiviral characteristics of HIV-1 attachment inhibitor BMS-626529, the active component of the prodrug BMS-663068. Antimicrob Agents Chemother. 2012 Jul;56(7):3498-507.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA